Ranbaxy Laboratories is currently trading at Rs. 473.70, up by 4.70 points or 1.00% from its previous closing of Rs. 469.00 on the BSE.
Ranbaxy Laboratories reportedly has filed applications seeking to sell drugs in the US, which will be manufactured at its Gurgaon plant, which is not among those barred by the US Food and Drug Administration (FDA). The company has five manufacturing facilities that are registered with the FDA, including Paonta Sahib, Mohali, Toansa, Gurgaon, and Dewas.
Ranbaxy’s Gurgaon plant has a pilot manufacturing line and the company could it scale it up the facility for commercial use, if it secured product approvals from there.
Ranbaxy’s three formulation manufacturing facilities at Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh) and Mohali (Punjab) have received the FDA’s import alert. Further, US regulator has also barred supply of drugs from Ranbaxy’s active pharmaceutical ingredient manufacturing plant in Toansa (Punjab) to the US.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
No comments:
Post a Comment